05:50:18 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-27 Kvartalsrapport 2024-Q2
2024-05-08 Kvartalsrapport 2024-Q1
2024-05-02 Ordinarie utdelning LIFE 0.00 NOK
2024-04-30 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-05-08 Ordinarie utdelning LIFE 0.00 NOK
2023-04-18 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-09 Ordinarie utdelning LIFE 0.00 NOK
2022-05-06 Årsstämma 2022
2022-04-21 Bokslutskommuniké 2021
2021-09-30 Extra Bolagsstämma 2021
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-10 Ordinarie utdelning LIFE 0.00 NOK
2021-05-07 Årsstämma 2021
2021-04-20 Bokslutskommuniké 2020
2020-06-26 Årsstämma 2020
2020-06-01 Bokslutskommuniké 2019
2019-02-07 Split LIFE 4:1
2018-12-11 Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2024-01-23 08:00:00

Bergen, Norway, 23 January 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has appointed Renete Kaarvik as Chief Financial Officer effective 1 Mai, 2024.

Kaarvik joins Lifecare from the position as Global Finance Officer at Grieg Seafood ASA, a position she has held for close to six years. 

Lifecares main operational focus is to establish automated manufacturing by end of Q2 2024, including preparations for market launch in the veterinary market. As part of the company’s growth strategy, the Board of Directors wish to strengthen the company’s executive management with focus on financial management and strategy. In addition to the expectation of increased commercial activities that will bring the company into a new phase, the Board of Directors wish to explore the potential of uplisting Lifecare to Oslo Børs Main Market. 

“We are very pleased to welcome Renete to Lifecare. She brings valuable competence and experience to the Lifecare Group. During the last year we have repeatedly highlighted the importance of establishing solid product and manufacturing fundaments, based on proven research and systemic quality management. With this appointment we establish the CFO position to further strengthen the Group capacities. We are confident that Renete will play an important role on forming the Groups financial strategies aligned with our growth strategy and strengthen the fundament for both the product and Group organization to the best of the shareholders’ interests", says Lifecare CEO Joacim Holter. 

Kaarvik graduated in 2004 from Macquarie University, Sydney, Australia, with a Master of Applied Finance. She also holds a Master of Science in Business from Bodø Graduate School of Business (1998). 

In addition to the aforementioned professional experience, Kaarvik has held Group Controller, Compliance Officer and Finance Manager positions in Mowi ASA and Marine Farms ASA, as well as Manager and Senior Associate positions in Ernst & Young and PricewaterhouseCoopers within Transaction and Business Advisory Services and Auditing. Furthermore, Kaarvik’s professional experience also include Senior Associate, Project Manager and Associate positions within private equity at HitecVision Private Equity and Arthur Andersen (Portugal).